Browse IQGAP3

Summary
SymbolIQGAP3
NameIQ motif containing GTPase activating protein 3
Aliases Ras GTPase-activating-like protein IQGAP3
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00307 Calponin homology (CH) domain
PF00612 IQ calmodulin-binding motif
PF00616 GTPase-activator protein for Ras-like GTPase
PF03836 RasGAP C-terminus
Function

-

> Gene Ontology
 
Biological Process GO:0000082 G1/S transition of mitotic cell cycle
GO:0000187 activation of MAPK activity
GO:0007265 Ras protein signal transduction
GO:0008361 regulation of cell size
GO:0030879 mammary gland development
GO:0032147 activation of protein kinase activity
GO:0032535 regulation of cellular component size
GO:0033598 mammary gland epithelial cell proliferation
GO:0033599 regulation of mammary gland epithelial cell proliferation
GO:0033601 positive regulation of mammary gland epithelial cell proliferation
GO:0033674 positive regulation of kinase activity
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0044770 cell cycle phase transition
GO:0044772 mitotic cell cycle phase transition
GO:0044843 cell cycle G1/S phase transition
GO:0045860 positive regulation of protein kinase activity
GO:0048732 gland development
GO:0050673 epithelial cell proliferation
GO:0050678 regulation of epithelial cell proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0061180 mammary gland epithelium development
GO:0070371 ERK1 and ERK2 cascade
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0090066 regulation of anatomical structure size
Molecular Function GO:0005516 calmodulin binding
GO:0017016 Ras GTPase binding
GO:0017022 myosin binding
GO:0017048 Rho GTPase binding
GO:0031267 small GTPase binding
GO:0032027 myosin light chain binding
GO:0051020 GTPase binding
GO:0070853 myosin VI binding
GO:0070856 myosin VI light chain binding
Cellular Component GO:0016328 lateral plasma membrane
> KEGG and Reactome Pathway
 
KEGG hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-195258: RHO GTPase Effectors
R-HSA-5626467: RHO GTPases activate IQGAPs
R-HSA-162582: Signal Transduction
R-HSA-194315: Signaling by Rho GTPases
Summary
SymbolIQGAP3
NameIQ motif containing GTPase activating protein 3
Aliases Ras GTPase-activating-like protein IQGAP3
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between IQGAP3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolIQGAP3
NameIQ motif containing GTPase activating protein 3
Aliases Ras GTPase-activating-like protein IQGAP3
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of IQGAP3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolIQGAP3
NameIQ motif containing GTPase activating protein 3
Aliases Ras GTPase-activating-like protein IQGAP3
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of IQGAP3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.730.0199
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.0080.407
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5250.56
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6860.181
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.6570.73
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.7330.782
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.0520.903
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.3770.782
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.6460.634
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.2710.714
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.0030.998
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.5020.00057
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of IQGAP3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.11.49.70.0589
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.11.79.40.0895
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.85.9-1.11
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)86016.7-16.70.429
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91644.46.238.20.0403
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59600600.0275
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 472514.310.71
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.97.40.51
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.615.4-1.81
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolIQGAP3
NameIQ motif containing GTPase activating protein 3
Aliases Ras GTPase-activating-like protein IQGAP3
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of IQGAP3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolIQGAP3
NameIQ motif containing GTPase activating protein 3
Aliases Ras GTPase-activating-like protein IQGAP3
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of IQGAP3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by IQGAP3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolIQGAP3
NameIQ motif containing GTPase activating protein 3
Aliases Ras GTPase-activating-like protein IQGAP3
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of IQGAP3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolIQGAP3
NameIQ motif containing GTPase activating protein 3
Aliases Ras GTPase-activating-like protein IQGAP3
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of IQGAP3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolIQGAP3
NameIQ motif containing GTPase activating protein 3
Aliases Ras GTPase-activating-like protein IQGAP3
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between IQGAP3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolIQGAP3
NameIQ motif containing GTPase activating protein 3
Aliases Ras GTPase-activating-like protein IQGAP3
Chromosomal Location1q21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting IQGAP3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.